For instance, bispecific monoclonal antibodies like IBI 3002 (targeting IL-4Rα and TSLP) [85] and lunsekimig (targeting TSLP and IL-13) [86] aim to address both T2 and non-T2 inflammation in asthma. Here, IL13 is linked to asthma.